Elder Pharmaceuticals Ltd (NSE– ELDERPHARM) an integrated pharmaceuticals company headquartered in Mumbai has posted robust results for the fourth quarter ended March 2011 (Q4 FY2011). As per the consolidated unaudited provisional results taken on record on May 10th, 2011, the income from operations has gone up to Rs 302.71 Crore for Q4-FY2011 as compared to Rs. 189.69 Crore during the corresponding quarter in the previous year. The consolidated operating profit (PBIDT) too has gone up to Rs. 52.35 Crore for Q4 FY2011 reflecting a growth of 40% over the previous corresponding quarter’s figure of Rs. 37.48 Crore. The consolidated Net Profit for Q4 FY2011 stood at Rs. 17.28 Crore. The consolidated EPS on a non – annualized basis stood at Rs. 8.41 for Q4 FY2011 and at Rs. 30.03 for FY2011.
For the twelve months ended March 2011, the unaudited consolidated sales turnover is Rs. 959.20 Cr (previous 12 months– Rs. 720.90 Cr - audited) up by 33% and the unaudited Net Profit is Rs. 61.67 Cr (previous 12 months – Rs 55.40 Cr - audited) up by 11%.
During the quarter under review, the Company completed its NCD raising program to augment medium to long term resources including regular capital expenditure. First tranche of Rs. 118.80 Crore and Second Tranche of Rs. 73.00 Crore were completed on 23rd Dec'2010 and 31st March 2011 respectively.
The Company launched I-Vit Plus and Somazina Plus during the quarter under review.
- I-Vit Plus is a blend of micro-nutrients helpful in providing adequate mineral/vitamin and essential nutrient supplementation for correcting suboptimal vitamin/mineral intake.
- Somazina Plus is a unique combination of Citicholine with Piracetam that improves brain function and stimulates the central nervous system thus offering neuroprotection and enhancing cognition.
Elder Pharmaceuticals has presence in niche therapeutic segments like Women’s healthcare, Wound care, Nutraceuticals /vitamin Supplements, Cardiology, Diabetes, Dermatology, Antibiotics and neurology. It is the market leader in calcium supplements (Shelcal), wound healing and injectable B12 vitamin. The company has a judicious mix of drug formulations, and active pharma ingredients (APIs). It has 6 manufacturing plants in India located in Maharashtra, Uttarakhand & Himachal Pradesh. The company has a state-of-the-art Research & Development Centre at Navi Mumbai which is recognized by the Department of Scientific & Industrial Research, Ministry of Science & Technology. (www.elderindia.com).
